Cure8 research brief
People with moderate-to-severe UC may have blood clotting changes and higher platelet activity that could raise thromboembolic risk; this study links those changes more to systemic inflammation than to local gut disease severity.
Clinicians treating UC patients, researchers studying thrombosis in IBD, and patients with moderate-to-severe ulcerative colitis, especially those with elevated systemic inflammation.
This abstract reports a single-center case–control study comparing coagulation and platelet function in 23 patients with moderate-to-severe ulcerative colitis (Mayo endoscopic subscore ≥2) who had failed prior therapy and were awaiting anti‑JAK treatment, versus 23 matched healthy controls.
The investigators used standard coagulation assays, rotational thromboelastometry, and whole-blood impedance aggregometry, and measured systemic (CRP) and mucosal (fecal calprotectin) inflammation.
Results showed higher Factor VIII and X activities, shortened clot formation time, increased maximum clot firmness across multiple assays, and enhanced platelet aggregation (ADP and ASPI tests) in UC patients versus controls.
Correlations suggested these procoagulant changes were associated with systemic inflammation (CRP) rather than localized intestinal inflammation or endoscopic disease scores.
The authors conclude that moderate-to-severe UC is associated with a hypercoagulable state and increased platelet reactivity driven mainly by systemic inflammation, and they call for larger prospective studies to confirm mechanisms and guide clinical strategies.
This is a small, single‑center case–control study (n=23 patients) reported as an abstract; findings are hypothesis‑generating and need confirmation in larger prospective cohorts before changing clinical practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Long-term real-world data on filgotinib help patients and clinicians understand how durable benefits and risks are over 2 years, including likelihood of staying on therapy and changes in inflammation markers.
If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
